Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Immunodeficiency Diseases (PID): early-phase trial registry
1 of 4 indexed Primary Immunodeficiency Diseases (PID) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Primary Immunodeficiency Diseases (PID): 4 US clinical trials tracked, 1 recruiting.
Primary Immunodeficiency Diseases (PID) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Baxalta now part of Shire, running 3 of these trials.
Enrollment posture brief
Registry condition primary-immunodeficiency-diseases-pid
OPEN 1 | RECR 25% | LATE 1 | EARLY 2 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Primary Immunodeficiency Diseases (PID) lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Immunodeficiency Diseases (PID) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Immunodeficiency Diseases (PID) is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
Takeda
NCT06076642
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
Baxalta now part of Shire
NCT02593188
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Baxalta now part of Shire
NCT01485796
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Baxalta now part of Shire
NCT00782106
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Immunodeficiency Diseases (PID) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Immunodeficiency Diseases (PID) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Immunodeficiency Diseases (PID) page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Primary Immunodeficiency Diseases (PID) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baxalta now part of Shire sponsors the most Primary Immunodeficiency Diseases (PID) trials on record, review their full trial history before evaluating a specific study. See Baxalta now part of Shire's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Immunodeficiency Diseases (PID) condition card totals 4 registered trials; most-linked intervention Recombinant human hyaluronidase; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.